Article
Multidisciplinary Sciences
R. Charles Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O'Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Summary: This study reports the clinical trial results of samuraciclib as an anti-cancer treatment, showing its clinical activity in patients with triple negative breast cancer and HR+/HER2- breast cancer.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Matthias Fischer, Lucas Moreno, David S. Ziegler, Lynley Marshall, C. Michel Zwaan, Meredith S. Irwin, Michela Casanova, Constantino Sabado, Beate Wulff, Mario Stegert, Luojun Wang, Felipe K. Hurtado, Fabrice Branle, Birgit Geoerger, Johannes H. Schulte
Summary: This study investigated the safety, pharmacokinetics, and efficacy of ceritinib in paediatric patients with ALK-positive malignancies. Results showed that the recommended dose for paediatric patients with ALK-positive malignancies is 500 mg/m(2) of ceritinib, which demonstrated promising antitumor activity.
Article
Oncology
Melissa L. Johnson, Manish R. Patel, Raid Aljumaily, Suzanne F. Jones, Howard A. Burris, David R. Spigel
Summary: This study evaluated the combination of oral LCL161 and oral topotecan in patients with relapsed/refractory small cell lung cancer and select gynecological cancers. The results showed that the combination therapy resulted in more myelosuppression and did not improve patient outcomes.
Article
Oncology
Da Li, Hong Pan, Wei Wang, Yanan Xue, Yong Fang, Haizhou Lou, Qin Pan, Wei Jin, Yu Zheng, Weidong Han, Kongli Zhu, Xianfeng Zhao, Rong Xu, Jin Han, Hongming Pan
Summary: Ametumumab, a fully human recombinant anti-EGFR monoclonal antibody, showed good tolerance and safety in patients with advanced solid malignancies and exhibited potential effectiveness.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim M. Linton, Martine E. D. Chamuleau, David John Lewis, Anna Sureda Balari, David Cunningham, Roberto S. Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Kuo-mei Chen, Tahamtan Ahmadi, Pieternella J. Lugtenburg
Summary: This study aimed to evaluate the safety and recommended dose of a novel bispecific antibody epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results showed that the full dose of 48 mg was identified as the recommended phase 2 dose, and no maximum tolerated dose was reached during the treatment. Epcoritamab demonstrated good antitumor activity in some patients during the study.
Article
Oncology
Kiyohiko Hatake, Takaaki Chou, Toshihiko Doi, Yasuhito Terui, Harumi Kato, Takayuki Hirose, Sachiko Seo, Michael Pourdehnad, Yumi Ogaki, Hiroshi Fujimoto, Patrick R. Hagner, Kazuhito Yamamoto
Summary: Avadomide, a novel cereblon-binding agent, showed acceptable toxicity profile and clinically meaningful efficacy in Japanese patients with advanced solid tumors or NHL, with an overall response rate of 54%.
Article
Computer Science, Theory & Methods
Belmiro P. M. Duarte, Anthony C. Atkinson, Nuno M. C. Oliveira
Summary: Dose escalation trials are important for optimizing drug administration and minimizing adverse effects. This study proposes a mixed integer nonlinear programming approach for computing optimal experimental designs for dose escalation, considering individual allocation and prognostic factors.
STATISTICS AND COMPUTING
(2022)
Article
Hematology
Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander Spira, Andrew Davies, John Radford, Tobias Menne, Anand Karnad, Jasmine M. Zain, Paul Fields, Karin Havenith, Hans G. Cruz, Shui He, Joseph Boni, Jay Feingold, Jens Wuerthner, Steven Horwitz
Summary: This study evaluated a novel anti-CD25 antibody-drug conjugate in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, showing potential efficacy in classical Hodgkin lymphoma and overall antitumour activity. The drug demonstrated good safety profile in the patient population studied.
LANCET HAEMATOLOGY
(2021)
Article
Hematology
Hongmei Jing, Li Yang, Junyuan Qi, Lugui Qiu, Chengcheng Fu, Junmin Li, Min Yang, Ming Qi, Ni Fan, Jia Ji, Jiajia Lu, Yunan Li, Jie Jin
Summary: Daratumumab monotherapy has shown favorable safety and efficacy in Chinese patients with relapsed/refractory multiple myeloma, making it a viable treatment option.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Ferry A. L. M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J. Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Ken Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B. El-Khoueiry
Summary: This study investigates the potential of Ivuxolimab in the treatment of cancer. The results demonstrate that Ivuxolimab is well tolerated and safe, and shows anti-tumor activity. Additionally, this study also finds that Ivuxolimab can activate the immune system, enhancing T-cell activation and proliferation, and has a certain control effect on tumors.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Aparna Hegde, Priyamvada Jayaprakash, Coline A. Couillault, Sarina Piha-Paul, Daniel Karp, Jordi Rodon, Shubham Pant, Siqing Fu, Ecaterina E. Dumbrava, Timothy A. Yap, Vivek Subbiah, Priya Bhosale, Cristian Coarfa, Jack P. Higgins, Eric T. Williams, Thomas F. Wilson, JoAnn Lim, Funda Meric-Bernstam, Elizabeth Sumner, Hira Zain, Di Nguyen, Ly M. Nguyen, Kimal Rajapakshe, Michael A. Curran, David S. Hong
Summary: The study investigated the combination of hypoxia-alleviating drug evofosfamide with immune checkpoint inhibitor ipilimumab for the treatment of cancers. Results showed partial responses in some patients, with preexisting immune gene signatures predicting treatment response and hypermetabolic tumors predicting disease progression.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
David M. Loeb, Ji Won Lee, Daniel A. Morgenstern, Yvan Samson, Anne Uyttebroeck, Chuhl Joo Lyu, An Van Damme, Karsten Nysom, Margaret E. Macy, Alexandra P. Zorzi, Julia Xiong, Petra Pollert, Ingrid Joerg, Yulia Vugmeyster, Mary Ruisi, Hyoung Jin Kang
Summary: In paediatric patients with refractory/relapsed solid tumours, avelumab monotherapy showed a safety profile consistent with previous adult studies, but clinical benefits were limited.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Xiaoxue Zhu, Yanhua Ding, Qian Wang, Guiyu Yang, Liang Zhou, Qingyu Wang
Summary: HLX22 is a novel monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2). This phase 1 dose-escalation study aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HLX22 in patients with advanced solid tumors. The study found that HLX22 demonstrated good tolerability and potential therapeutic effects in HER2-overexpressing advanced or metastatic solid tumors.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Farasat Kazmi, Shibani Nicum, Rene L. Roux, Laura Spiers, Chat Gnanaranjan, Ajithkumar Sukumaran, Hani Gabra, Essam Ghazaly, Nigel W. McCracken, David J. Harrison, Sarah P. Blagden
Summary: The combination of NUC-1031 and carboplatin is well tolerated in recurrent ovarian cancer, with the highest efficacy observed in the NUC-1031 dose cohort of 500 mg/m(2) administered on days 1 and 8 with AUC5 carboplatin. This therapeutic combination remains attractive even in patients with platinum-resistant disease.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Helen Barnett, Oliver Boix, Dimitris Kontos, Thomas Jaki
Summary: This article examines the impact of employing backfilling in phase I dose-escalation studies on the estimation of the maximum tolerated dose and the duration of the study. The study finds that backfilling can increase the accuracy of selecting the maximum tolerated dose and reduce the trial duration. However, the use of backfilling comes at the cost of increased sample size.
